Introduction

Pharmacovigilance (PV) plays a critical role in ensuring patient safety by monitoring, detecting, assessing, and preventing adverse effects associated with medicinal products. While developed nations have established robust PV systems, developing countries are still navigating the path toward building efficient, sustainable, and compliant frameworks.

Over the past decade, significant progress has been made in strengthening PV systems across these regions; however, challenges related to infrastructure, regulatory maturity, and resource limitations persist. This article explores the current landscape of pharmacovigilance in developing nations, highlighting progress, key challenges, and opportunities for capacity building.

As healthcare systems continue to evolve across emerging markets, pharmacovigilance in developing countries has become increasingly important for strengthening patient safety, improving adverse event reporting, and supporting regulatory compliance.

1- Progress in Pharmacovigilance Systems

Developing countries have made notable strides in establishing foundational PV systems, often supported by global health organizations and regulatory harmonization efforts.

Key Developments:

• Establishment of National Pharmacovigilance Centers responsible for collecting and managing adverse event (AE) reports.
• Integration into global safety databases such as WHO’s Programme for International Drug Monitoring.
• Adoption of structured reporting systems and standard operating procedures (SOPs).
• Increasing awareness among healthcare professionals (HCPs) regarding AE reporting.

Roles and Responsibilities:

• Regulatory Authorities: Oversight of PV systems, signal detection, and risk communication.
• Marketing Authorization Holders (MAHs): Collection, evaluation, and submission of safety data.
• Healthcare Professionals: Identification and reporting of adverse events.
• PV Service Providers: Supporting case processing, literature screening, and compliance activities.

Regulatory Procedures:

• Implementation of expedited reporting timelines (e.g., 7- and 15-day reporting).
• Periodic Safety Update Reports (PSURs) submission requirements.
• Development of risk management plans (RMPs).

2- Key Challenges in Developing Nations

Despite progress, several barriers hinder the effectiveness and sustainability of PV systems in developing countries.

Major Challenges:

• Underreporting of Adverse Events: Due to limited awareness and lack of training among HCPs.
• Resource Constraints: Insufficient funding, infrastructure, and skilled personnel.
• Fragmented Regulatory Frameworks: Lack of harmonized guidelines across regions.
• Limited Digitalization: Dependence on manual or semi-automated systems.
• Data Quality Issues: Incomplete or inconsistent safety reports.

Impact on Stakeholders:

• Regulators: Difficulty in timely signal detection and risk assessment.
• MAHs: Increased compliance risks and operational inefficiencies.
• Patients: Potential delays in identifying and mitigating safety risks.

3- Capacity Building and Strengthening PV Systems

To address these challenges, capacity building remains a cornerstone for sustainable pharmacovigilance systems.

Strategic Approaches:

• Training and Education: Continuous professional development programs for HCPs and PV professionals.
• Regulatory Strengthening: Development of clear guidelines aligned with international standards (e.g., ICH, WHO).
• Digital Transformation: Implementation of electronic reporting systems and safety databases.
• Public Awareness Campaigns: Encouraging patient reporting and engagement.
• Partnerships and Outsourcing: Leveraging expertise from specialized PV service providers.

Roles and Responsibilities:

• Governments: Investment in infrastructure and policy development.
• International Organizations: Providing technical support and training.
• Private Sector: Supporting innovation and operational excellence.
• Academic Institutions: Incorporating PV into healthcare curricula.

Regulatory Procedures:

• Establishment of inspection and audit frameworks.
• Standardization of case processing and quality checks.
• Implementation of pharmacovigilance system master files (PSMFs).

Organizations seeking to strengthen pharmacovigilance capabilities often benefit from external expertise in case processing, regulatory compliance, safety reporting, and quality management through Baupharma Pharmacovigilance Service.

4- The Role of Collaboration and Global Integration

Collaboration is essential for accelerating PV maturity in developing regions.

Key Enablers:

• Regional harmonization initiatives (e.g., African Medicines Agency, ASEAN efforts).
• Data sharing and signal detection through global networks.
• Joint training programs and knowledge exchange platforms.

Benefits:

• Improved consistency in regulatory expectations.
• Enhanced data quality and signal detection capabilities.
• Faster response to emerging safety concerns

5- Future Outlook for Pharmacovigilance in Developing Countries

Continued investment in regulatory infrastructure, workforce development, digital technologies, and international collaboration will be critical for advancing pharmacovigilance maturity in developing countries. As reporting systems become more integrated and harmonized with global standards, these regions are expected to play an increasingly important role in global drug safety monitoring.

Key Takeaways

• Developing nations have made significant progress in establishing pharmacovigilance systems, but gaps remain.
• Underreporting, limited resources, and regulatory fragmentation are major challenges.
• Capacity building through training, digitalization, and regulatory strengthening is essential.
• Collaboration between stakeholders and global integration are critical for sustainable PV systems.
• A proactive, structured approach to pharmacovigilance enhances patient safety and regulatory compliance.